Here are the 10-K annual reports from Donaldson Company, Inc. (DCI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow DCI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DCI filings page.
Donaldson Company, Inc. reported fiscal 2026 net sales of $3,885.6 million, up 5.3% from $3,690.9 million in fiscal 2025. Net earnings were $453.8 million versus $367.0 million, and diluted earnings per share were $3.85 versus $3.05. Mobile Solutions sales increased 5.6% to $2,419.7 million and pretax earnings rose 11.9% to $467.5 million. Life Sciences sales increased 12.8% to $333.2 million, with pretax earnings of $32.3 million. Industrial Solutions pretax earnings fell 21.3% to $155.6 million; the company cited operational inefficiencies related to shifting Power Generation production and unfavorable sales mix.
Donaldson acquired Facet on May 4, 2026, for $830.2 million in cash consideration; the acquisition contributed $30.3 million to Industrial Solutions sales. Operating cash flow was $493.7 million, while cash used in investing activities was $879.5 million, primarily due to Facet. Long-term debt was $1,280.0 million as of July 31, 2026, and total debt represented 42.9% of capitalization, compared with 31.5% a year earlier. For fiscal 2027, Donaldson expects capital expenditures of $70 million to $90 million.
Donaldson Company, Inc. reports a diversified global filtration business with four regional splits: U.S./Canada 44.2%, EMEA 27.8%, APAC 17.2% and LATAM 10.8%. The company emphasizes three strategic priorities: extend market access, expand technologies and pursue strategic acquisitions. As of Jan 31, 2025, non-affiliate market value was $8,462,489,351 and 115,907,357 shares were outstanding as of Sep 12, 2025. Fiscal 2025 R&D spending was $87.8 million (2.4% of net sales). Backlog within 90 days declined to $552.2 million from $574.7 million. The company recorded $62.0 million of intangible impairment in FY2025 related to bioprocessing ($46.6M Univercells, $15.4M Solaris). During FY2025 it repurchased 4.9 million shares for $333.6 million and maintained a $600 million revolving credit facility with additional accordion capacity.